BiotechTube

Capsaicin Topical Solution

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Osteoarthritis, Knee

Conditions

Osteoarthritis, Knee

Trial Timeline

Jul 1, 2016 → Oct 1, 2016

NCT ID
NCT03124407

About Capsaicin Topical Solution

Capsaicin Topical Solution is a approved stage product being developed by Astellas Pharma for Osteoarthritis, Knee. The current trial status is completed. This product is registered under clinical trial identifier NCT03124407. Target conditions include Osteoarthritis, Knee.

What happened to similar drugs?

20 of 20 similar drugs in Osteoarthritis, Knee were approved

Approved (20) Terminated (1) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅duloxetineEli LillyApproved
✅ImrecoxibJiangsu Hengrui MedicineApproved
✅Etoricoxib (Arcoxia) + Sugar pillMerckApproved
✅zoledronic acidNovartisApproved
✅LumiracoxibNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03124407ApprovedCompleted

Competing Products

20 competing products in Osteoarthritis, Knee

See all competitors
ProductCompanyStageHype Score
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
Duloxetine + Sugar pillEli LillyApproved
43
UBX0101 or placeboUnity BiotechnologyPre-clinical
8
UBX0101Unity BiotechnologyPhase 1
19
UBX0101Unity BiotechnologyPhase 2
25
UBX0101Unity BiotechnologyPhase 1
19
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
35
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
35
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
35
Duloxetine + PlaceboShionogiPhase 3
40
DuloxetineShionogiPhase 3
40
ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part DOno PharmaceuticalPhase 1
29
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
27
Duloxetine + PlaceboEli LillyPhase 3
40